Gliknik Inc.
Gliknik Inc. is a privately owned corporation committed to the discovery and development of novel biomolecules for autoimmune diseases and cancer. The company capitalizes on its expertise in immunology and tumor immunology. Gliknik’s lead compounds are novel T cell vaccines in clinical safety studies. Gliknik also has created recombinant mimetics of intravenous immune globulin and recombinant mimetics of monoclonal antibodies.
Contact Name:
David Block
President & CEO
Address:
801 W. Baltimore Street
Suite 501A
Baltimore Maryland 21201
United StatesEmail:
Website:
News
Gliknik Announces Interim Clinical Data
Posted December 20, 2012
Gliknik Raises $4.9 Million
Posted October 8, 2012
Gliknik Publishes Preclinical Data on Stradomer(TM) Program for Autoimmune Disease
Posted September 13, 2012
Baltimore's Gliknik nabs $1.5M from National Cancer Institute
Posted October 4, 2011
Pages
- ‹ previous
- 1
- 2
- 3
- next ›